Phytopharm's Early Stage Licensing Approach: Retaining Upside and Control
Executive Summary
Phytopharm's Phase I deal with Yamanouchi could prove a viable model for cash-strapped biotechs seeking funding to push their drugs into later-stage development without ceding future upside.